Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
An expert analysis has concluded that evidence-based guidance from the American Radium Society Appropriate Use Criteria (ARS AUC) Thoracic Committee on several treatment modalities for locally advanced non–small cell lung cancer (LA-NSCLC)—which accounts for 20% to 30% of lung cancer cases at diagnosis—does have utility for optimizing multidisciplinary care in this challenging patient population.
Findings were published online today in JAMA Oncology, with the study investigators noting the need for their review stems from the most recent appropriate use criteria for these patients came out in 2014 and the publication since then of studies examining radiation therapy technique and dosing, and systemic therapy selection. Their systematic literature review involved relevant articles from PubMed—69 references comprising 30 well-designed studies, 9 moderately well-designed studies, 2 studies with design limitations, and 28 nonprimary data references—that were published between January 1966 and December 2022 and focused on combined chemoradiation therapy, dose escalation, consolidation systemic therapy, and palliative radiotherapy.
“Information regarding the treatment of recurrent disease either locally or with oligometastatic disease after primary treatment for LA-NSCLC is increasingly available and should be integrated into modern clinical decision-making,” they wrote. “Additionally, the use of molecular markers such as EGFR, ALK, and PD-L1 has significantly informed systemic therapy options for many patients with NSCLC, and their integration into LA-NSCLC treatment pathways needs to be clarified.”
This consensus-based document encompasses key practice paradigms and 6 typical clinical scenarios in patients with unresectable disease, which covers most patients who have LA-NSCLC, the authors noted:
The ARS AUC Thoracic Committee, citing a lack of uniform guidance, delivers 3 summary recommendations from their review:
“Treatment appropriateness of a variety of LA-NSCLC scenarios was assessed by a consensus-based modified Delphi approach using a range of 3 points to 9 points to denote consensus agreement,” the authors explained regarding how they arrived at their recommendations.
The authors also highlight the importance of multidisciplinary input and shared decision-making with patients who have LA-NSCLC during treatment discussions, concluding that “various surgical, radiotherapeutic, and systemic options are available to manage this challenging patient population.”
Reference
Rodrigues G, Higgins KA, Rimner A, et al. American Radium Society appropriate use criteria for unresectable locally advanced non–small cell lung cancer. JAMA Oncol. Published online April 11, 2024. doi:10.1001/jamaoncol.2024.0294
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More